Immupharma Share Discussion Threads

[newtothisgame3] 11/4/2019 10:55

#IMM triggered a breakout alert.
👀🔥🚀 LOOK

[newtothisgame3] 10/4/2019 07:15

!FOLLOWFEED!YOUTUBEVIDEO:Dos61J1kLTU:
Lupuzor™ - ImmuPharma

ImmuPharma says article shines light on potential of peptide subsidiary
07:35 26 Feb 2019
Peptide drugs generated US$30bn in sales last year

ImmuPharma PLC (LON:IMM) said peer-reviewed journal Nature Communications has carried an article assessing the potential of Urelix, a technology developed by its subsidiary Ureka.

The periodical has described for the first time the unique properties of oligourea foldamers as tools to improve the pharmaceutical properties of peptides.

There are more than 7,000 naturally occurring peptides that have crucial roles in human physiology, including actions as hormones, neurotransmitters and growth factors.

Around 140 peptide therapeutics are currently being developed, while currently around 60 have been approved by the US Food & Drug Administration generating sales last year of US$30bn.

However, as Dimitri Dimitriou, ImmuPharma's chief executive, pointed out: “Using natural peptides as drugs is not so effective because they are quickly broken down.

“To put it simply, our technology overcomes these challenges and represents an intelligent way to design novel drugs.”

One of the first areas of focus for the Ureka researchers has been lookalikes for GLP-1, the basis of a number of drugs used to treat type II diabetes and non-alcoholic liver disease.

Scientists are also assessing the potential of using the Urelix to develop cancer drug candidates and as means of improving products already on the market.

The work of the Ureka began in 2014 and the ImmuPharma offshoot has a tie-up with France’s Centre National de la Recherche Scientifique.


Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM),says lupus treatment Lupuzor will be entered into managed access programme to allow sufferers whose doctors recommend it.

Immupharma will get 'real-world' data from the MAP with up to 500 patients to receive the drug free of charge for two years.

That is more than twice the number of patients studied in all clinical trials for Lupuzor to date.

One big advantage is that' real-world' data can be used to supplement a regulatory filing.

Merck's Keytruda I/O cancer treatment made use MAP extensively for example.

An extension study to Lupozor's phase III study will also report next year, said McCarthy.

[ken chung] 09/4/2019 18:19

Down it goes.That's your money disappearing.

[newtothisgame3] 06/4/2019 21:29

#IMM April 5, 2019
Research Community Calls for Updates to EULAR Recommendations for Lupus Management

[newtothisgame3] 05/4/2019 10:47

US$30bn in sales last year #ImmuPharma PLC (LON:#IMM) said peer-reviewed journal Nature Communications has carried an article assessing the potential of Urelix, a technology developed by its subsidiary Ureka.

[newtothisgame3] 05/4/2019 10:40

Lupuzor open-label extension study, from the original Phase III trial, with a total of 62 eligible patients recruited throughout the US and Europe, remains on track to report results in the second quarter of 2019.

[newtothisgame3] 04/4/2019 09:11

#IMM write up 👍🔥👀💼8188;💼ԁ88;💼💼;💼💼💼💼

[wigwammer] 03/4/2019 21:50

"For once I agree with you."Aside from when you followed me into SKP and RENE :)

[nobbygnome] 03/4/2019 21:09

>> wiggie

For once I agree with you.

Surely you are not still invested in IMM....

[wigwammer] 03/4/2019 21:06

Youngharry - presumably the £2m given to incanthera is paying Tim's wages there as well. He is now making two incomes from the Imm cash! Given the success evident at both companies he is clearly worth it :)

[borromini1] 03/4/2019 09:39

cap pick spambot - posting click bait again and again and again ...

Giving this post the thumbs down will not improve the absence of quality in your posts spambot.

[newtothisgame3] 03/4/2019 09:04

#IMM  Lupuzor’s Phase III safety data in SLE
— Anticipated future use of #lupuzor in clinical practice April 3, 2019

[sandeep67] 03/4/2019 08:58

Chug along Cheng. you clearly lost a packet in this plum company, but you have to let go mate. You'll need to take anti depressants if you let it get to you mate

[ken chung] 03/4/2019 08:46

Another biotech failure .

[ken chung] 02/4/2019 15:54

Lemmings and mushrooms only now.

[borromini1] 02/4/2019 10:24

cap pick spambot - You are confusing a secured bank loan with a speculative investment that has dropped in value.

[newtothisgame3] 02/4/2019 09:33

£2M + Interest

[borromini1] 02/4/2019 09:30

So what “fair value” will Immupharma’s auditors accept for a 16.5% share holding in Incanthera for last years accounts? And now?

[newtothisgame3] 02/4/2019 07:13

NO CASH IS LOCKED IN FOOL

[youngharry2] 02/4/2019 07:08

In making this deal why did not a single IMM director or advisor ask the question what if? What if after investing £2m in cash, terms are not agreed and Incanthara doesn't spend £1m to progress the Nucant programme. Well they have the answer now: £2m of IMM cash locked up in an unlisted company that can't raise cash which means £2m less to progress Lupuzor and reputational damage that will cost existing shareholders dear when IMM needs to raise cash. Negligent to say the least.

[ken chung] 01/4/2019 16:05

Bad news gathering momentum. Lemmings and mushrooms only now.

[newtothisgame3] 01/4/2019 12:58

#ImmuPharma #IMM
is continuing to engage with potential corporate partners that can support the full release of #Lupuzor, designed to treat autoimmune disease lupus, over the longer term.

[borromini1] 01/4/2019 09:22

Nobby - presumably Incanthera have failed to raise the capital or secure funding to cover the future development costs for the Nucant programme, therefore it is not viable for Incanthara to commit £1m to buying the licence. This means Immupharma is free to find another licence partner for Nucant, but with a lack of detail over why things went wrong at Incanthera the notion of a broader collaboration seems to be a euphemism for Immupharma not knowing when it can liquidate last years premature £2m investment in Incanthara.

[buywell2] 01/4/2019 08:26

Strike 1 .... Strike 2 .....


buywell2 - 24 Feb 2019 - 19:00:31 - 33977 of 34013 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM

what is a placebo ? read this


buywell3 - 27 Apr 2018 - 10:19:34 - 29505 of 33977 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM
Phase 3 trials are very pricey

To sign up a meaningful number of human guinea pigs to be injected with a trial drug compound ... with unknown toxicology outcomes ... you could be looking at several millions of pounds.

Where is the money coming from after the recent Phase 3 results came out poor at best ie no proven efficay ie the compound didn't do anything measurable that was different to a placebo ie a fake drug/pill that some human guinea pigs have to take at phase 3 in order to see if those taking the real deal drug being tested derive any benefit from taking it ie it has efficacy.

efficacy is the whole reason for a phase 3 clinical trial to see if the drug being tested works

Put me down for one of those please nurse